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Complicated intraabdominal infection (cIAI) is widely 
considered as a common disease in clinical practice 
nowadays. Even though surgical procedures for source 
control have been improved over the past decades, one 
of the key components in treatment of cIAIs is adequate 
antimicrobial therapy. 
From diagnostic uncertainty, broad-spectrum and 
combined antimicrobial therapy are usually administered 
for patients with cIAIs to cover all possible pathogens. 
Moreover, clinicians have difficulties in recognizing when 
to provide and when to withhold antimicrobial therapy (1). 
This trend resulted in increased antimicrobial resistance 
and the pandemic spread of highly resistant pathogens. 
For these reasons, currently used guidelines from the 
Surgical Infection Society (SIS) (2) and the Infectious 
Diseases Society of America (IDSA) (3) suggest diagnostic 
approach for  microbiology,  t iming of  ini t iat ion, 
recommended regimens according to severity of disease 
based on highly qualified evidences. These guidelines also 
recommend the course of 4 to 7 days of antimicrobial 
therapy in patients with adequate source control and 
positive clinical response. Recently, Sawyer et al. even 
published “Trial of short-course antimicrobial therapy 
for intraabdominal infections (STOP-IT)” (4), which 
concluded that clinical outcomes including recurrent 
intraabdominal infections were similar after 4-day antibiotic 
therapy compared to those after longer courses of therapy. 
However, clinicians remain still in traditional manner 
to continue antimicrobial therapy until clinical evidences 
become clear. This is why most of patients are treated 
with antibiotics in average duration of 10 to 14 days (5,6). 
Especially in critically ill patients, no concrete warrant 
is recommended except small series of single-center, 
retrospective studies (7-9). 
In this respect, the DURAPOP randomized clinical trial 
conducted by Montravers et al. (10) handled clinical impact 
of short duration of antimicrobial therapy in critically ill 
patients with postoperative intraabdominal infections. The 
authors designed a multicenter, prospective, controlled, 
randomized study comparing 8-day antibiotic therapy to 
15-day therapy. Two hundred and forty-nine enrolled 
patients with cIAIs admitted to intensive care units 
(ICUs) after adequate source control .  The study 
suggested that the number of antibiotic-free days was 
higher in the 8-day arm (15 days in the 8-day arm vs. 
12 days in the 15-day arm, P<0.0001) corresponding on a 15% 
relative reduction in antibiotic exposure. However, the 45-day 
mortality rates and length of ICU stay did not differ between 
the two groups. Moreover, it did not detect any difference in 
the rates of emergence of multi-drug resistant bacteria except 
for Pseudomonas aeruginosa between the two groups. 
Unlike previous reports (4,11) showing the effect of 
short-course treatment focused on patients with mild-to-
moderate community-acquired peritonitis or appendicitis, 
this report included critically ill ICU patients with 
postoperative IAIs. To apply short-course antimicrobial 
therapy in patients with extreme severity of illness, it 
suggested the definition of “short-course” was much longer 
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(8-day) than that of other studies. 
As it is expected that shortening of the duration of 
antimicrobial therapy can reduce the emergence of MDR 
pathogens, this result might be disappointing in a way. Even 
though, the emergence of MDR bacteria can be influenced 
by various factors including spectrum or combination 
of agents as well as duration of therapy. Therefore, the 
superiority in emergence of MDR bacteria might not be 
obtained just by comparing duration of therapy. 
In conclusion, short-course antimicrobial therapy 
is valuable to be considered in critically ill patients 
with postoperative IAIs corresponding with this trial. 
Nevertheless, the discontinuation should be decided 
depending on thorough understanding of controlling 
infectious source and each patient’s status. 
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